GRI Bio Revenue and Competitors
Estimated Revenue & Valuation
- GRI Bio's estimated annual revenue is currently $1.9M per year.
- GRI Bio's estimated revenue per employee is $155,000
Employee Data
- GRI Bio has 12 Employees.
- GRI Bio grew their employee count by 20% last year.
GRI Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
GRI Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is GRI Bio?
GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 12 | 9% | N/A |
#2 | $1M | 12 | N/A | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1.8M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |